Implementation and outcomes of a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) monoclonal antibody treatment program at an academic medical center serving a high-risk patient population

Antimicrob Steward Healthc Epidemiol. 2021 Jun 24;1(1):e3. doi: 10.1017/ash.2021.165. eCollection 2021.
No abstract available